Novavax (NVAX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Novavax (NVAX) is set to release its Q2 2025 earnings on August 6th, with projections of a loss of ($0.12) per share and revenue of $149.19 million.
• The company's recent earnings report revealed a substantial profit of $2.93 EPS, significantly surpassing analysts' expectations and showcasing a 610.3% increase in year-over-year revenue.
• Currently, Novavax has an average rating of "Hold" from analysts, with price targets ranging from $6.00 to $15.86, indicating cautious outlooks amid mixed ratings.

Novavax (NASDAQ:NVAX - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Novavax to post earnings of ($0.12) per share and revenue of $149.19 million for the quarter. Novavax has set its FY 2025 guidance at EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating the consensus estimate of $0.71 by $2.22. The firm had revenue of $666.66 million for the quarter, compared to analysts' expectations of $204.08 million. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The business's quarterly revenue was up 610.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.05) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Performance

NASDAQ NVAX traded up $0.11 during trading on Monday, hitting $6.67. The stock had a trading volume of 722,007 shares, compared to its average volume of 6,384,550. The company has a market capitalization of $1.08 billion, a PE ratio of 2.52, a P/E/G ratio of 0.08 and a beta of 2.50. The company's 50-day moving average price is $6.94 and its two-hundred day moving average price is $7.22. Novavax has a 12 month low of $5.01 and a 12 month high of $15.22.

Analysts Set New Price Targets

NVAX has been the topic of a number of analyst reports. B. Riley reiterated a "buy" rating on shares of Novavax in a research note on Monday, May 19th. Bank of America dropped their price objective on Novavax from $10.00 to $9.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 22nd. Citigroup initiated coverage on Novavax in a research note on Tuesday, June 17th. They set a "sell" rating and a $6.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday, May 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Novavax currently has an average rating of "Hold" and a consensus price target of $15.86.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NVAX. AQR Capital Management LLC increased its holdings in shares of Novavax by 95.2% during the 1st quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company's stock worth $285,000 after acquiring an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Novavax by 2.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company's stock worth $678,000 after acquiring an additional 2,750 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Novavax during the 1st quarter worth approximately $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Novavax by 16.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company's stock worth $2,005,000 after acquiring an additional 44,105 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Novavax during the 1st quarter worth approximately $167,000. 53.04% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.